BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

CERAM Signs Agreement With AstraZeneca PLC (AZN)


1/18/2013 9:37:11 AM

18 January 2013, Stoke-on-Trent, UK - AstraZeneca, a global pharmaceutical company, has signed an agreement with Ceram Research Ltd, the international materials development company, for Ceram to develop its Inorganic-based Controlled Release Technology in a feasibility study for the delivery of selected AstraZeneca compounds.

“This technology, if successfully implemented, could provide AstraZeneca with an alternative formulation approach for delivering these compounds,” said Ceram CEO, Tony Kinsella.

Controlled Release Technology is just one of the development projects that Ceram’s team of materials experts is currently working on; others include multi-element substituted hydroxyapatite for orthopaedic device coating applications.

With Healthcare as one of its largest markets, the materials development business has ambitious plans to continue its growth in the US and Europe.

Tony Kinsella continued: “Our work is focussed on commercial development of materials for industrial applications – exactly what a recent news item on the BBC said was lacking in Britain. We have, for example, recently helped Greatbatch Medical to gain FDA (510K) approval of a coating implant submission. We have also worked with GlaxoSmithKline in the proving of its Sensodyne toothpaste – a product that has seen substantial annual growth over the last decade, creating significant incomes for both GSK and the UK.”

For more information visit www.ceram.com/crt

About Ceram

Ceram is an independent, international materials technology company that focuses on innovation, sustainability and quality assurance of materials.

Headquartered in Staffordshire, UK, and with approved laboratories around the world, Ceram solves product and process challenges across a range of materials to help clients improve performance, comply with regulations and develop their sustainability performance in order to gain a competitive advantage and increase profitability.

Ceram operates in a wide variety of sectors around the world.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->